BeiGene Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
11,000
- Stock Symbol
-
06160
- Investments
-
12
- Share Price
-
$19.53
- (As of Wednesday Closing)
BeiGene General Information
Description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Contact Information
Website
www.beigene.com.cnCorporate Office
- 30 Science Park Road
- Zhongguancun Life Science Park
- Beijing, 102206
- China
Corporate Office
- 30 Science Park Road
- Zhongguancun Life Science Park
- Beijing, 102206
- China
BeiGene Stock Performance
As of 23-Apr-2025, BeiGene’s stock price is $19.53. Its current market cap is $29B with 1.4B shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $19.53 | $19.27 | $10.60 - $22.88 | $29B | 1.4B | 5.25M | -$0.47 |
BeiGene Financials Summary
As of 31-Dec-2024, BeiGene has a trailing 12-month revenue of $3.81B.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 18,870,506 | 18,870,506 | 17,118,766 | 21,074,459 |
| Revenue | 3,810,241 | 3,810,241 | 2,458,779 | 1,415,921 |
| EBITDA | (409,075) | (409,075) | (812,170) | (1,947,239) |
| Net Income | (644,786) | (644,786) | (881,708) | (2,003,815) |
| Total Assets | 5,920,910 | 5,920,910 | 5,805,275 | 6,379,290 |
| Total Debt | 1,079,866 | 1,079,866 | 930,185 | 596,675 |
BeiGene Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BeiGene Comparisons
Industry
Financing
Details
BeiGene Competitors (49)
One of BeiGene’s 49 competitors is Syndax, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Syndax | Formerly VC-backed | Waltham, MA | ||||
| Celldex Therapeutics | Formerly VC-backed | Hampton, NJ | ||||
| Polaris Group (California) | Formerly PE-Backed | Grand Cayman, Cayman Islands | ||||
| Innovent Biologics | Formerly PE-Backed | Shanghai, China | ||||
| Alphamab Oncology | Formerly VC-backed | Suzhou, China |
BeiGene Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BeiGene Patents
BeiGene Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250122152-A1 | Kat6 inhibitors | Pending | 27-Sep-2023 | ||
| EP-4539882-A1 | Methods of treating lymphoma using anti-tigit antibodies | Pending | 15-Jun-2023 | ||
| US-20240425523-A1 | Compounds for the degradation of egfr kinase | Pending | 31-May-2023 | ||
| US-20240368177-A1 | 5-amino-6,8-dihydro-1h-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide derivatives as mta-cooperative inhibitors of prmt5 | Pending | 30-Mar-2023 | ||
| US-20240301051-A1 | Anti-cldn6 antibodies and methods of use | Pending | 06-Mar-2023 | A61P35/00 |
BeiGene Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BeiGene Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BeiGene Investments & Acquisitions (12)
BeiGene’s most recent deal was a Early Stage VC with Recorna Bio. The deal was made on 28-Jun-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Recorna Bio | 28-Jun-2024 | Early Stage VC | Drug Discovery | ||
| Ensem (Global Rights To Experimental Cancer Therapy) | 21-Nov-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Duo Oncology | 11-Aug-2023 | Seed Round | Discovery Tools (Healthcare) | ||
| Strand Therapeutics | 28-Nov-2022 | Later Stage VC | Drug Discovery | ||
| BeiGene (42 Acre Site in Hopewell, New Jersey) | 23-Nov-2021 | Corporate Asset Purchase | Buildings and Property |
BeiGene ESG
Risk Overview
Risk Rating
Updated March, 05, 2025
23.32 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Biotechnology
Subindustry
of 371
Rank
Percentile
BeiGene Exits (1)
BeiGene’s most recent exit was on 24-Jan-2020 from Leap Therapeutics. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Leap Therapeutics | 24-Jan-2020 | Completed |
|
BeiGene FAQs
-
When was BeiGene founded?
BeiGene was founded in 2010.
-
Where is BeiGene headquartered?
BeiGene is headquartered in Beijing, China.
-
What is the size of BeiGene?
BeiGene has 11,000 total employees.
-
What industry is BeiGene in?
BeiGene’s primary industry is Drug Discovery.
-
Is BeiGene a private or public company?
BeiGene is a Public company.
-
What is BeiGene’s stock symbol?
The ticker symbol for BeiGene is 06160.
-
What is the current stock price of BeiGene?
As of 23-Apr-2025 the stock price of BeiGene is $19.53.
-
What is the current market cap of BeiGene?
The current market capitalization of BeiGene is $29B.
-
What is BeiGene’s current revenue?
The trailing twelve month revenue for BeiGene is $3.81B.
-
Who are BeiGene’s competitors?
Syndax, Celldex Therapeutics, Polaris Group (California), Innovent Biologics, and Alphamab Oncology are some of the 49 competitors of BeiGene.
-
What is BeiGene’s annual earnings per share (EPS)?
BeiGene’s EPS for 12 months was -$0.47.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
